Search This Blog

Monday, September 28, 2020

Immunic mid-stage study of IMU-838 in COVID-19 passes first safety tollgate

Immunic (NASDAQ:IMUX) announces that its Phase 2 clinical trial, CALVID-1, evaluating IMU-838 in patients with moderate COVID-19 disease will continue unchanged after the independent Data Monitoring Committee completed its preplanned interim safety analysis.

Thus far, 110 subjects have been enrolled and the trial is progressing well. Target enrollment is ~230 participants.

The company says IMU-838 is an orally available, next-generation immune modulator that dampens the immune response by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH) that plays a key role in intracellular metabolism of activated immune cells.

https://seekingalpha.com/news/3617573-immunic-mid-stage-study-of-imuminus-838-in-covidminus-19-patients-passes-first-safety

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.